Ardelyx, Inc. (ARDX)
$
5.86
+0.05 (0.85%)
Key metrics
Financial statements
Free cash flow per share
-0.2300
Market cap
1.4 Billion
Price to sales ratio
3.6571
Debt to equity
1.4810
Current ratio
4.3020
Income quality
0.9486
Average inventory
23 Million
ROE
-0.3657
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines aimed at treating various gastrointestinal and cardiorenal conditions both in the United States and internationally. The company's lead product candidate, tenapanor, has successfully completed Phase III clinical trials for treating patients suffering from irritable bowel syndrome with constipation and is also undergoing Phase III trials to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD) undergoing dialysis, a condition known as hyperphosphatemia. Ardelyx is additionally developing RDX013, a potassium secretagogue designed to address elevated serum potassium levels, or hyperkalemia, which is particularly relevant for certain patients with kidney or heart disorders. Furthermore, RDX020 is being investigated as an early-stage program targeting metabolic acidosis, a serious electrolyte imbalance affecting patients with CKD. The company has established collaborations with Kyowa Kirin for development in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. for China, and Knight Therapeutics, Inc. in Canada for commercializing tenapanor in those regions. The company's financial metrics show that the EBITDA is -$16,713,000.00 a key indicator of the company's operational profitability, while the gross profit stands at $283,059,000.00 highlighting its earnings from core operations. The weighted average number of diluted shares outstanding is 235,233,000.00 which reflects potential dilution effects, and the company reported depreciation and amortization expenses of $2,063,000.00 illustrating the wear and tear of its assets. Ardelyx’s stock is identified with the symbol 'ARDX' in the market. Investors may find the stock appealing, as it is affordable at $4.61 making it suitable for budget-conscious individuals. The stock boasts a high average trading volume of 4,492,222.00 indicating strong liquidity and interest from the market. With a market capitalization of $1,412,160,380.00 Ardelyx is classified as a small-cap player, which often indicates growth potential. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth in the Healthcare sector. This positioning enhances its ability to attract attention from both investors and collaborators in the field of biopharmaceuticals.
Is Ardelyx, Inc. (ARDX) a good investment?
Investing in Ardelyx, Inc. (ARDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Ardelyx, Inc. (ARDX)'s stock forecast?
Analysts predict Ardelyx, Inc. stock to fluctuate between $3.21 (low) and $7.18 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ardelyx, Inc.'s market capitalization?
As of 2025-08-20, Ardelyx, Inc.'s market cap is $1,412,160,380, based on 240,983,000 outstanding shares.
How does Ardelyx, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Ardelyx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ardelyx, Inc. (ARDX) stock?
To buy Ardelyx, Inc. (ARDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Ardelyx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ardelyx, Inc. stock ever split?
Ardelyx, Inc.'s last stock split was 4:1 on 2021-07-20.
How did Ardelyx, Inc. perform in the last earnings report?
Revenue: $333,615,000 | EPS: -$0.17 | Growth: -43.33%.
Where can I find Ardelyx, Inc.'s investor relations reports?
Visit https://www.ardelyx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ardelyx, Inc.?
You can explore historical data from here
What is the all-time high and low for Ardelyx, Inc. stock?
All-time high: $10.13 (2024-02-12) | All-time low: $0.49 (2022-06-16).
What are the key trends affecting Ardelyx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing increased demand and sales growth in Q2 versus Q1.
seekingalpha.com
Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane Foster - Chief Commercial Officer Justin A. Renz - Chief Financial & Operations Officer Michael G.
zacks.com
The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Ardelyx (ARDX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.07 per share a year ago.
prnewswire.com
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
